Grifols SA
(NASDAQ : GRFS)

( )
GRFS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.82%158.250.7%$1178.31m
MRKMerck & Co., Inc. 0.13%76.550.7%$1001.47m
PFEPfizer Inc. 0.03%37.180.9%$1001.25m
ABBVAbbVie, Inc. -1.05%107.061.9%$822.51m
BMYBristol-Myers Squibb Co. -0.14%63.521.0%$732.21m
LLYEli Lilly & Co. 0.13%182.731.1%$687.69m
AZNAstraZeneca Plc 1.73%50.041.2%$439.51m
GSKGlaxoSmithKline Plc 0.58%36.250.2%$182.68m
RPRXRoyalty Pharma Plc 0.00%41.430.2%$160.14m
NVSNovartis AG -0.10%86.530.2%$151.19m
VTRSViatris, Inc. 0.46%13.030.0%$128.36m
RGENRepligen Corp. 0.00%212.866.8%$92.84m
CVACCureVac NV 4.44%99.900.0%$77.91m
ATNF180 Life Sciences Corp. 0.28%10.820.0%$64.48m
SNYSanofi 0.66%50.490.2%$60.78m

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.